Jia Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jia Zheng has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Yonghui Dong
Department of Orthopedics, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China
6 shared publications Meng Zhang
Department of Orthopedics, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Henan University People’s Hospital
5 shared publicationsYonghui Dong
Department of Orthopedics, China
4 shared publicationsYunke Liu
Department of Orthopedics, China
4 shared publicationsLikang Xiao
Department of Orthopedics, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Henan University People’s Hospital
3 shared publicationsXiao Chen
Department of Orthopedics, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Henan University People’s Hospital
3 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1889984
Correction: Hesperidin ameliorates dexamethasone-induced osteoporosis by inhibiting p53
- 23 July 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1889984
Open AccessCorrection: Hesperidin ameliorates dexamethasone-induced osteoporosis by inhibiting p53
- Open Access
- 5 August 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1597219
Identification of immune-related diagnostic genes and immune cell infiltration in aseptic loosening of prostheses after total hip arthroplasty by integrated bioinformatics analysis and experimental confirmation
Background: Aseptic loosening (AL) of hip prostheses is one of the main reasons for revision total hip arthroplasty (rTHA). However, the transcriptomic characteristics of AL are scarcely understood. This study aimed to discover candidate biomarkers for the diagnosis of AL.Patients and methods: The interface membrane from four patients with AL of hip prostheses and the synovium samples from four patients with a periprosthetic femoral fracture (PFF) after total hip arthroplasty (THA) were analyzed via RNA sequencing. Integrated bioinformatics analysis was employed to identify immune-related hub genes in AL. Immune cell infiltration analysis and correlation analysis were performed. Connectivity map analysis was utilized to predict the potential small-molecule compounds for AL treatment. Western blotting and histological staining were used to verify the expression of hub genes in AL.Results: A total of 2,184 differentially expressed genes (DEGs) were identified in the AL samples, including 2,050 upregulated genes and 134 downregulated genes, and these DEGs were mainly enriched in immune cell-related signaling pathways and immune-related processes. Immune cell infiltration analysis showed that the proportion of M1 macrophages increased in AL. Three genes closely related to M1 macrophages were screened, namely, CD68, CD163, and SPP1, according to the results of correlation analysis. Hematoxylin–eosin staining showed that the synovitis score of AL samples was significantly higher than that of controls (average, 6.2 vs. 3.8). Western blotting and immunohistochemical analysis showed that the expression of CD68, CD163, and SPP1 in the AL group was significantly higher than that in the control group. The top 10 compounds with the highest negative scores were predicted to be potential therapeutic drugs for the treatment of AL.Conclusion: Preliminary transcriptomic signatures suggested that CD68, CD163, and SPP1 may serve as potential biomarkers for AL, offering a novel research perspective for future diagnosis and therapeutic intervention of AL.
- 5 August 2025
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 16, 1597219
Open AccessIdentification of immune-related diagnostic genes and immune cell infiltration in aseptic loosening of prostheses after total hip arthroplasty by integrated bioinformatics analysis and experimental confirmation
Background: Aseptic loosening (AL) of hip prostheses is one of the main reasons for revision total hip arthroplasty (rTHA). However, the transcriptomic characteristics of AL are scarcely understood. This study aimed to discover candidate biomarkers for the diagnosis of AL.Patients and methods: The interface membrane from four patients with AL of hip prostheses and the synovium samples from four patients with a periprosthetic femoral fracture (PFF) after total hip arthroplasty (THA) were analyzed via RNA sequencing. Integrated bioinformatics analysis was employed to identify immune-related hub genes in AL. Immune cell infiltration analysis and correlation analysis were performed. Connectivity map analysis was utilized to predict the potential small-molecule compounds for AL treatment. Western blotting and histological staining were used to verify the expression of hub genes in AL.Results: A total of 2,184 differentially expressed genes (DEGs) were identified in the AL samples, including 2,050 upregulated genes and 134 downregulated genes, and these DEGs were mainly enriched in immune cell-related signaling pathways and immune-related processes. Immune cell infiltration analysis showed that the proportion of M1 macrophages increased in AL. Three genes closely related to M1 macrophages were screened, namely, CD68, CD163, and SPP1, according to the results of correlation analysis. Hematoxylin–eosin staining showed that the synovitis score of AL samples was significantly higher than that of controls (average, 6.2 vs. 3.8). Western blotting and immunohistochemical analysis showed that the expression of CD68, CD163, and SPP1 in the AL group was significantly higher than that in the control group. The top 10 compounds with the highest negative scores were predicted to be potential therapeutic drugs for the treatment of AL.Conclusion: Preliminary transcriptomic signatures suggested that CD68, CD163, and SPP1 may serve as potential biomarkers for AL, offering a novel research perspective for future diagnosis and therapeutic intervention of AL.
- Open Access
- 3 January 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 31 (3) , 1-13
Application of integrated omics in aseptic loosening of prostheses after hip replacement
Aseptic loosening (AL) of artificial hip joints is the most common complication following hip replacement surgery. A total of eight patients diagnosed with AL following total hip arthroplasty (THA) undergoing total hip replacement and eight control patients diagnosed with avascular necrosis of femoral head (ANFH) or femoral neck fracture undergoing THA were enrolled. The samples of the AL group were from synovial tissue surrounding the lining/head/neck of the prosthesis, and the samples of the control group were from the synovium in the joint cavity. The present study utilized second‑generation high‑throughput sequencing and mass spectrometry to detect differentially expressed genes, proteins and metabolites in the samples, as well as Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. Key genes cytokine receptor‑like factor‑1 (CRLF1) and glutathione‑S transferase µ1 (GSTM1) expression levels were verified by reverse transcription‑quantitative PCR and western blotting. The integrated transcriptomics, proteomics and untargeted metabolomics analyses revealed characteristic metabolite changes (biosynthesis of guanine, L‑glycine and adenosine) and decreased CRLF1 and GSTM1 in AL, which were primarily associated with amino acid metabolism and lipid metabolism. In summary, the present study may uncover the underlying mechanisms of AL pathology and provide stable and accurate biomarkers for early warning and diagnosis.
- 3 January 2025
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 31 (3) , 1-13
Open AccessApplication of integrated omics in aseptic loosening of prostheses after hip replacement
Aseptic loosening (AL) of artificial hip joints is the most common complication following hip replacement surgery. A total of eight patients diagnosed with AL following total hip arthroplasty (THA) undergoing total hip replacement and eight control patients diagnosed with avascular necrosis of femoral head (ANFH) or femoral neck fracture undergoing THA were enrolled. The samples of the AL group were from synovial tissue surrounding the lining/head/neck of the prosthesis, and the samples of the control group were from the synovium in the joint cavity. The present study utilized second‑generation high‑throughput sequencing and mass spectrometry to detect differentially expressed genes, proteins and metabolites in the samples, as well as Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. Key genes cytokine receptor‑like factor‑1 (CRLF1) and glutathione‑S transferase µ1 (GSTM1) expression levels were verified by reverse transcription‑quantitative PCR and western blotting. The integrated transcriptomics, proteomics and untargeted metabolomics analyses revealed characteristic metabolite changes (biosynthesis of guanine, L‑glycine and adenosine) and decreased CRLF1 and GSTM1 in AL, which were primarily associated with amino acid metabolism and lipid metabolism. In summary, the present study may uncover the underlying mechanisms of AL pathology and provide stable and accurate biomarkers for early warning and diagnosis.
- 4 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt A) , 113071
Lactate-upregulated ARG2 expression induces cellular senescence in fibroblast-like synoviocytes of osteoarthritis via activating the mTOR/S6K1 signaling pathway
- 4 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt A) , 113071
Lactate-upregulated ARG2 expression induces cellular senescence in fibroblast-like synoviocytes of osteoarthritis via activating the mTOR/S6K1 signaling pathway
- Open Access
- 29 July 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1431452
Identification of diagnostic genes and drug prediction in metabolic syndrome-associated rheumatoid arthritis by integrated bioinformatics analysis, machine learning, and molecular docking
Background: Interactions between the immune and metabolic systems may play a crucial role in the pathogenesis of metabolic syndrome-associated rheumatoid arthritis (MetS-RA). The purpose of this study was to discover candidate biomarkers for the diagnosis of RA patients who also had MetS.Methods: Three RA datasets and one MetS dataset were obtained from the Gene Expression Omnibus (GEO) database. Differential expression analysis, weighted gene co-expression network analysis (WGCNA), and machine learning algorithms including Least Absolute Shrinkage and Selection Operator (LASSO) regression and Random Forest (RF) were employed to identify hub genes in MetS-RA. Enrichment analysis was used to explore underlying common pathways between MetS and RA. Receiver operating characteristic curves were applied to assess the diagnostic performance of nomogram constructed based on hub genes. Protein−protein interaction, Connectivity Map (CMap) analyses, and molecular docking were utilized to predict the potential small molecule compounds for MetS-RA treatment. qRT-PCR was used to verify the expression of hub genes in fibroblast-like synoviocytes (FLS) of MetS-RA. The effects of small molecule compounds on the function of RA-FLS were evaluated by wound-healing assays and angiogenesis experiments. The CIBERSORT algorithm was used to explore immune cell infiltration in MetS and RA.Results: MetS-RA key genes were mainly enriched in immune cell-related signaling pathways and immune-related processes. Two hub genes (TYK2 and TRAF2) were selected as candidate biomarkers for developing nomogram with ideal diagnostic performance through machine learning and proved to have a high diagnostic value (area under the curve, TYK2, 0.92; TRAF2, 0.90). qRT-PCR results showed that the expression of TYK2 and TRAF2 in MetS-RA-FLS was significantly higher than that in non-MetS-RA-FLS (nMetS-RA-FLS). The combination of CMap analysis and molecular docking predicted camptothecin (CPT) as a potential drug for MetS-RA treatment. In vitro validation, CPT was observed to suppress the cell migration capacity and angiogenesis capacity of MetS-RA-FLS. Immune cell infiltration results revealed immune dysregulation in MetS and RA.Conclusion: Two hub genes were identified in MetS-RA, a nomogram for the diagnosis of RA and MetS was established based on them, and a potential therapeutic small molecule compound for MetS-RA was predicted, which offered a novel research perspective for future serum−based diagnosis and therapeutic intervention of MetS-RA.
- 29 July 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1431452
Open AccessIdentification of diagnostic genes and drug prediction in metabolic syndrome-associated rheumatoid arthritis by integrated bioinformatics analysis, machine learning, and molecular docking
Background: Interactions between the immune and metabolic systems may play a crucial role in the pathogenesis of metabolic syndrome-associated rheumatoid arthritis (MetS-RA). The purpose of this study was to discover candidate biomarkers for the diagnosis of RA patients who also had MetS.Methods: Three RA datasets and one MetS dataset were obtained from the Gene Expression Omnibus (GEO) database. Differential expression analysis, weighted gene co-expression network analysis (WGCNA), and machine learning algorithms including Least Absolute Shrinkage and Selection Operator (LASSO) regression and Random Forest (RF) were employed to identify hub genes in MetS-RA. Enrichment analysis was used to explore underlying common pathways between MetS and RA. Receiver operating characteristic curves were applied to assess the diagnostic performance of nomogram constructed based on hub genes. Protein−protein interaction, Connectivity Map (CMap) analyses, and molecular docking were utilized to predict the potential small molecule compounds for MetS-RA treatment. qRT-PCR was used to verify the expression of hub genes in fibroblast-like synoviocytes (FLS) of MetS-RA. The effects of small molecule compounds on the function of RA-FLS were evaluated by wound-healing assays and angiogenesis experiments. The CIBERSORT algorithm was used to explore immune cell infiltration in MetS and RA.Results: MetS-RA key genes were mainly enriched in immune cell-related signaling pathways and immune-related processes. Two hub genes (TYK2 and TRAF2) were selected as candidate biomarkers for developing nomogram with ideal diagnostic performance through machine learning and proved to have a high diagnostic value (area under the curve, TYK2, 0.92; TRAF2, 0.90). qRT-PCR results showed that the expression of TYK2 and TRAF2 in MetS-RA-FLS was significantly higher than that in non-MetS-RA-FLS (nMetS-RA-FLS). The combination of CMap analysis and molecular docking predicted camptothecin (CPT) as a potential drug for MetS-RA treatment. In vitro validation, CPT was observed to suppress the cell migration capacity and angiogenesis capacity of MetS-RA-FLS. Immune cell infiltration results revealed immune dysregulation in MetS and RA.Conclusion: Two hub genes were identified in MetS-RA, a nomogram for the diagnosis of RA and MetS was established based on them, and a potential therapeutic small molecule compound for MetS-RA was predicted, which offered a novel research perspective for future serum−based diagnosis and therapeutic intervention of MetS-RA.
- Open Access
- 28 June 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (7) , e9131
Slipped capital femoral epiphysis in an adolescent with congenital adrenal hyperplasia: A case report
Key Clinical Message: In previous reports, hypothyroidism, hypopituitrism, and hypogonadism were common endocrine causes of SCFE, but this is the first time that congenital adrenal hyperplasia has been observed. As such, patients who have undergone long‐term endocrine treatment for congenital adrenal hyperplasia could potentially be subjected to a higher risk for SCFE.
- 28 June 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (7) , e9131
Open AccessSlipped capital femoral epiphysis in an adolescent with congenital adrenal hyperplasia: A case report
Key Clinical Message: In previous reports, hypothyroidism, hypopituitrism, and hypogonadism were common endocrine causes of SCFE, but this is the first time that congenital adrenal hyperplasia has been observed. As such, patients who have undergone long‐term endocrine treatment for congenital adrenal hyperplasia could potentially be subjected to a higher risk for SCFE.
- 24 April 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 119, 110102
Isobavachalcone ameliorates the progression of osteoarthritis by suppressing NF-κB signaling pathway
- 24 April 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 119, 110102
Isobavachalcone ameliorates the progression of osteoarthritis by suppressing NF-κB signaling pathway
- Open Access
- 10 September 2022
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 30 (11) , 1443-1454
Phosphoproteomics reveals the BRAF-ERK1/2 axis as an important pathogenic signaling node in cartilage degeneration
- 10 September 2022
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 30 (11) , 1443-1454
Open AccessPhosphoproteomics reveals the BRAF-ERK1/2 axis as an important pathogenic signaling node in cartilage degeneration
- 1 September 2022
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 45 (9) , 1283-1290
Down-Regulation of Ubiquitin-Specific Peptidase 9X Inhibited Proliferation, Migration and Invasion of Osteosarcoma via ERK1/2 and PI3K/Akt Signaling Pathways
Ubiquitin-specific peptidase 9X (USP9X) has been reported to be closely associated with the formation and progression of a variety of malignant tumors. However, the mechanism by which USP9X is involved in osteosarcoma and development has not been clearly studied. This work aimed to probe the influence of USP9X on osteosarcoma cell proliferation, migration and invasion. This study recruited sixty-seven patients with histologically definited osteosarcoma. Osteosarcoma samples and cell-line were used to reflect the expression level of USP9X. Analysis of cell proliferation by thiazolium blue (MTT) assays. Transwell experiments and wound healing were used to verify cell migration and invasion capabilities. The effect of USP9X was investigated through in vivo experiments. USP9X-related pathway proteins were detected by Western blot and quantitative real-time PCR (qRT-PCR). The expression of USP9X in osteosarcoma was higher than that in adjacent tissues. The overall survival of patients with USP9X-negative patients was better than that of patients with USP9X-positive. The growth of osteosarcoma cells in vivo and in vitro was inhibited by USP9X inhibitor. Cell migration and invasion were significantly inhibited by down-regulation of USP9X. USP9X was involved in extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol-3-kinases/protein-serine-threonine kinase (PI3K/Akt) pathway in osteosarcoma cells. Proliferation, migration and invasion of osteosarcoma cells were inhibited by down-regulation of USP9X, and were related to the ERK1/2 and PI3K/Akt signaling pathways, therefore, it might probably become a new target for the prevention and treatment of osteosarcoma.
- 1 September 2022
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 45 (9) , 1283-1290
Down-Regulation of Ubiquitin-Specific Peptidase 9X Inhibited Proliferation, Migration and Invasion of Osteosarcoma via ERK1/2 and PI3K/Akt Signaling Pathways
Ubiquitin-specific peptidase 9X (USP9X) has been reported to be closely associated with the formation and progression of a variety of malignant tumors. However, the mechanism by which USP9X is involved in osteosarcoma and development has not been clearly studied. This work aimed to probe the influence of USP9X on osteosarcoma cell proliferation, migration and invasion. This study recruited sixty-seven patients with histologically definited osteosarcoma. Osteosarcoma samples and cell-line were used to reflect the expression level of USP9X. Analysis of cell proliferation by thiazolium blue (MTT) assays. Transwell experiments and wound healing were used to verify cell migration and invasion capabilities. The effect of USP9X was investigated through in vivo experiments. USP9X-related pathway proteins were detected by Western blot and quantitative real-time PCR (qRT-PCR). The expression of USP9X in osteosarcoma was higher than that in adjacent tissues. The overall survival of patients with USP9X-negative patients was better than that of patients with USP9X-positive. The growth of osteosarcoma cells in vivo and in vitro was inhibited by USP9X inhibitor. Cell migration and invasion were significantly inhibited by down-regulation of USP9X. USP9X was involved in extracellular signal-regulated kinase 1/2 (ERK1/2) and phosphatidylinositol-3-kinases/protein-serine-threonine kinase (PI3K/Akt) pathway in osteosarcoma cells. Proliferation, migration and invasion of osteosarcoma cells were inhibited by down-regulation of USP9X, and were related to the ERK1/2 and PI3K/Akt signaling pathways, therefore, it might probably become a new target for the prevention and treatment of osteosarcoma.
- Open Access
- 8 August 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 920824
Therapeutic potential of nanotechnology-based approaches in osteoarthritis
Osteoarthritis (OA) is a multifactorial disease that affects the entire joint, often resulting in severe pain, disability, psychological distress, and a lower quality of life. Patient self-management is emphasized in OA clinical recommendations. Currently, the clinical treatment of OA mainly focuses on pain relief and the improvement of joint function, with few options for regenerating degenerative cartilage or slowing the progression of OA. Therefore, we first reviewed the current treatment of OA, and then summarized the research advances of nanotechnology in OA treatment, including nano drug delivery systems for small molecule drugs, nucleic acids and proteins, nano-scaffolds for cartilage regeneration, and nanoparticle lubricants. Finally, we discussed the opportunities and potential challenges of nanotechnology in OA treatment.
- 8 August 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 920824
Open AccessTherapeutic potential of nanotechnology-based approaches in osteoarthritis
Osteoarthritis (OA) is a multifactorial disease that affects the entire joint, often resulting in severe pain, disability, psychological distress, and a lower quality of life. Patient self-management is emphasized in OA clinical recommendations. Currently, the clinical treatment of OA mainly focuses on pain relief and the improvement of joint function, with few options for regenerating degenerative cartilage or slowing the progression of OA. Therefore, we first reviewed the current treatment of OA, and then summarized the research advances of nanotechnology in OA treatment, including nano drug delivery systems for small molecule drugs, nucleic acids and proteins, nano-scaffolds for cartilage regeneration, and nanoparticle lubricants. Finally, we discussed the opportunities and potential challenges of nanotechnology in OA treatment.